Drug Profile
Praziquantel paediatric formulation - Pediatric Praziquantel Consortium
Alternative Names: arpraziquantel - Pediatric Praziquantel Consortium; L-praziquantel; L-praziquantel orodispersible; L-PZQ; L-PZQ ODT; MSC-1028703; MSC-1028703A; MSC-2499550A; PZQ ODT; Rac-PZQ ODT; Racemate PZQ ODTLatest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator Pediatric Praziquantel Consortium
- Class 3-ring heterocyclic compounds; Anthelmintics; Cyclohexanes; Isoquinolines; Pyrazines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Schistosomiasis
Most Recent Events
- 27 Dec 2023 Merck KGaA announces intention to submit regulatory application of praziquantel paediatric formulation for Schistosomiasis
- 15 Dec 2023 CHMP adopts a positive opinion for arpraziquantel for the treatment of Schistosomiasis (In children, In infants) in European Union
- 22 Jan 2023 The Pediatric Praziquantel Consortium intends to start the launch phase of praziquantel for product availability on a not-for-profit basis, initially in sub-Saharan African countries in 2024